Notice of NHLBI Participation in PAR-21-173 - "Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed)"
Notice Number:
NOT-HL-21-043

Key Dates

Release Date:

December 21, 2021

Related Announcements

PAR-21-173 - Support for Research Excellence - First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed)
PAR-21-169 - Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)
NOT-HL-21-042 - Notice of NHLBI Participation in PAR-21-169 - "Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed)"

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective on September 28, 2022 , in PAR-21-173 "Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)"

The following sections of PAR-21-173 have been modified to highlight NHLBI's participation in this FOA:

Currently Reads:

Part 1. Overview Information

Components of Participating Organizations

National Institute of General Medical Sciences (NIGMS)

National Eye Institute (NEI)

National Human Genome Research Institute (NHGRI)

National Institute on Aging (NIA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute on Deafness and Other Communication Disorders (NIDCD)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute on Drug Abuse (NIDA)

National Institute of Environmental Health Sciences (NIEHS)

National Institute of Neurological Disorders and Stroke (NINDS)

National Institute of Nursing Research (NINR)

National Cancer Institute (NCI)

Assistance Listing Number(s)


93.859, 93.172, 93.855, 93.279, 93.361, 93.853, 93.121, 93.113, 93.398, 93.866, 93.847, 93.867, 93.273, 93.865, 93.286, 93.173


Modified to Read (changes shown in bold italics):

Part 1. Overview Information

Components of Participating Organizations

National Institute of General Medical Sciences (NIGMS)

National Eye Institute (NEI)

National Human Genome Research Institute (NHGRI)

National Institute on Aging (NIA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute on Deafness and Other Communication Disorders (NIDCD)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute on Drug Abuse (NIDA)

National Institute of Environmental Health Sciences (NIEHS)

National Institute of Neurological Disorders and Stroke (NINDS)

National Institute of Nursing Research (NINR)

National Cancer Institute (NCI)

National Heart, Lung, and Blood Institute (NHLBI)


Assistance Listing Number(s)
93.859, 93.172, 93.855, 93.279, 93.361, 93.853, 93.121, 93.113, 93.398, 93.866, 93.847, 93.867, 93.273, 93.865, 93.286, 93.173 93.840, 93.837, 93.838, 93.839, 93.233

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Program Considerations
NHLBI provides global leadership forresearch, research training, and education program to promote the prevention and treatment of heart, lung, blood, and sleep diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives. The NHLBI encourages research designed to answer the breadth of scientific questions related to heart, lung, blood, and/or sleep diseases, disorders, and phenotypes. The NHLBI seeks applications that will address questions relevant to the NHLBI mission, address gaps in the NHLBI's portfolio, and should align with theNHLBI's Strategic Vision [PDF]. Please refer to the NHLBI website for more details on the research priorities of the NHLBI.

Section VII. Agency Contacts

Scientific/Research Contact(s)

Fernando P. Bruno, MD, MPH
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-496-0886
E-mail: fernando.bruno@nih.gov


Financial/Grants Management Contact(s)

Anthony Agresti
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-435-0513
E-mail: agrestia@nhlbi.nih.gov

Inquiries

Please direct all inquiries to:

Desir e L. Salazar, PhD
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-480-4177
E-mail: desiree.salazar@nih.gov